Literature DB >> 17316876

HBV pathogenesis in animal models: recent advances on the role of platelets.

Matteo Iannacone1, Giovanni Sitia, Zaverio M Ruggeri, Luca G Guidotti.   

Abstract

Hepatitis B virus (HBV) causes acute and chronic necroinflammatory liver diseases and hepatocellular carcinoma (HCC). HBV replicates noncytopathically in the hepatocyte, and most of the liver injury associated with this infection reflects the immune response. While the innate immune response may not contribute significantly to the pathogenesis of liver disease or viral clearance, the adaptive immune response, particularly the cytotoxic T lymphocyte (CTL) response, contributes to both. Recent observations also reveal that antigen-nonspecific inflammatory cells enhance CTL-induced liver pathology and, more surprisingly, that platelets facilitate the intrahepatic accumulation of CTLs, suggesting that the host response to HBV infection is a highly complex but coordinated process. The notion that platelets contribute to liver disease and viral clearance by promoting the recruitment of virus-specific CTLs into the liver is a new concept in viral pathogenesis, which may prove useful to implement treatments of chronic HBV infection in man.

Entities:  

Mesh:

Year:  2007        PMID: 17316876      PMCID: PMC1892635          DOI: 10.1016/j.jhep.2007.01.007

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  71 in total

1.  Viral clearance without destruction of infected cells during acute HBV infection.

Authors:  L G Guidotti; R Rochford; J Chung; M Shapiro; R Purcell; F V Chisari
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

2.  Differential expression of alpha3 fucosyltransferases in Th1 and Th2 cells correlates with their ability to bind P-selectin.

Authors:  C A van Wely; A D Blanchard; C J Britten
Journal:  Biochem Biophys Res Commun       Date:  1998-06-18       Impact factor: 3.575

Review 3.  Role of virus-induced apoptosis in a host defense mechanism against virus infection.

Authors:  A H Koyama; H Irie; T Fukumori; S Hata; S Iida; H Akari; A Adachi
Journal:  J Med Invest       Date:  1998-08

4.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells.

Authors:  V Henn; J R Slupsky; M Gräfe; I Anagnostopoulos; R Förster; G Müller-Berghaus; R A Kroczek
Journal:  Nature       Date:  1998-02-05       Impact factor: 49.962

5.  Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice.

Authors:  Y Nakamoto; L G Guidotti; V Pasquetto; R D Schreiber; F V Chisari
Journal:  J Immunol       Date:  1997-06-15       Impact factor: 5.422

6.  P-Selectin mediates reperfusion injury through neutrophil and platelet sequestration in the warm ischemic mouse liver.

Authors:  S S Yadav; D N Howell; D A Steeber; R C Harland; T F Tedder; P A Clavien
Journal:  Hepatology       Date:  1999-05       Impact factor: 17.425

Review 7.  Natural killer cells in antiviral defense: function and regulation by innate cytokines.

Authors:  C A Biron; K B Nguyen; G C Pien; L P Cousens; T P Salazar-Mather
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

8.  Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice.

Authors:  T Heise; L G Guidotti; V J Cavanaugh; F V Chisari
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  P-selectin glycoprotein ligand-1 (PSGL-1) on T helper 1 but not on T helper 2 cells binds to P-selectin and supports migration into inflamed skin.

Authors:  E Borges; W Tietz; M Steegmaier; T Moll; R Hallmann; A Hamann; D Vestweber
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

Review 10.  Mobilizing dendritic cells for tolerance, priming, and chronic inflammation.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307

View more
  31 in total

Review 1.  Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.

Authors:  María L Cuestas; Verónica L Mathet; José R Oubiña; Alejandro Sosnik
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

2.  Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus.

Authors:  Matteo Iannacone; Giovanni Sitia; Iñigo Narvaiza; Zaverio M Ruggeri; Luca G Guidotti
Journal:  Clin Vaccine Immunol       Date:  2007-09-19

3.  Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel.

Authors:  Jocelyn L Tan-Shalaby
Journal:  BMJ Case Rep       Date:  2014-09-01

Review 4.  Effector CD8 T cell trafficking within the liver.

Authors:  Luca G Guidotti; Matteo Iannacone
Journal:  Mol Immunol       Date:  2012-11-10       Impact factor: 4.407

Review 5.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

Review 6.  Immune Response in Hepatitis B Virus Infection.

Authors:  Anthony Tan; Sarene Koh; Antonio Bertoletti
Journal:  Cold Spring Harb Perspect Med       Date:  2015-07-01       Impact factor: 6.915

Review 7.  Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection.

Authors:  Kenichi Morikawa; Tomoe Shimazaki; Rei Takeda; Takaaki Izumi; Machiko Umumura; Naoya Sakamoto
Journal:  Ann Transl Med       Date:  2016-09

8.  Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B.

Authors:  Alessandro Allegra; Giuseppa Penna; Andrea Alonci; Angela Granata; Arianna D'Angelo; Caterina Musolino
Journal:  Med Oncol       Date:  2009-09-23       Impact factor: 3.064

9.  The L60V variation in hepatitis B virus core protein elicits new epitope-specific cytotoxic T lymphocytes and enhances viral replication.

Authors:  Yu Zhang; Yulin Ren; Yan Wu; Bao Zhao; Lipeng Qiu; Xiaodong Li; Dongping Xu; Jun Liu; George F Gao; Songdong Meng
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

10.  High seroprevalence of human herpesvirus type 8 in patients with hepatocellular carcinoma.

Authors:  C-C Su; K-C Tseng; M-N Lin; T-C Hsieh; T-Y Chu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-20       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.